Get the Stockscreener App
0.6031
5.54%
-0.0354
After Hours:
.61
0.0069
+1.14%
Leap Therapeutics Inc stock is traded at $0.6031, with a volume of 1.04M.
It is down -5.54% in the last 24 hours and up +101.98% over the past month.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
See More
Previous Close:
$0.6385
Open:
$0.6609
24h Volume:
1.04M
Relative Volume:
0.33
Market Cap:
$24.99M
Revenue:
$1.50M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.3611
EPS:
-1.67
Net Cash Flow:
$-55.17M
1W Performance:
-21.03%
1M Performance:
+101.98%
6M Performance:
+86.14%
1Y Performance:
-73.89%
1-Day Range:
$0.6017
$0.67
1-Week Range:
$0.6017
$0.777
52-Week Range:
$0.2223
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.6031 | 36.17M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-29-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Will Leap Therapeutics Inc. price bounce be sustainableJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
How cyclical is Leap Therapeutics Inc. (5MC) stock compared to rivalsJuly 2025 EndofMonth & Reliable Price Action Trade Plans - newser.com
Will Leap Therapeutics Inc. stock outperform growth indexesJuly 2025 EndofMonth & Real-Time Market Sentiment Alerts - newser.com
Developing predictive dashboards with Leap Therapeutics Inc. dataJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
How to forecast Leap Therapeutics Inc. trends using time seriesJuly 2025 Outlook & Weekly Top Gainers Alerts - newser.com
Will Leap Therapeutics Inc. outperform the marketMarket Risk Summary & Weekly High Potential Stock Alerts - newser.com
Will Leap Therapeutics Inc. stock maintain momentum in 2025Quarterly Earnings Report & Fast Exit/Entry Strategy Plans - newser.com
Is Leap Therapeutics Inc. meeting your algorithmic filter criteria2025 Historical Comparison & Entry Point Strategy Guides - newser.com
Institutional scanner results for Leap Therapeutics Inc.July 2025 Price Swings & Reliable Breakout Forecasts - newser.com
Will Leap Therapeutics Inc. (5MC) stock sustain uptrend momentumEarnings Summary Report & Community Trade Idea Sharing - newser.com
Leap Therapeutics Closes $58.88 Million Private Placement In Cash Led by Winklevoss Capital - citybiz
Leap Therapeutics raises $58.9 million for digital asset strategy By Investing.com - Investing.com Canada
Is Leap Therapeutics Inc. (5MC) stock vulnerable to rate hikesWeekly Volume Report & Capital Protection Trade Alerts - newser.com
Leap Therapeutics closes $58.9 million funding led by Winklevoss Capital - Investing.com Canada
$58.9M Raise: Leap Therapeutics and Winklevoss Capital to Build Digital Asset Treasury; Board Expanded - Stock Titan
Will Leap Therapeutics Inc. (5MC) stock profit from fiscal stimulusPortfolio Return Report & Stepwise Swing Trade Plans - newser.com
How interest rate cuts could boost Leap Therapeutics Inc. stockJuly 2025 Momentum & Free High Return Stock Watch Alerts - newser.com
Leap Therapeutics secures $58.9M PIPE to launch digital asset strategy; shares up 29% - MSN
Leap Therapeutics Granted Extension by Nasdaq - MSN
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion - MarketScreener
Why Is Leap Therapeutics Down 9% In Pre-Market Trading? - Benzinga
Leap Therapeutics: Blending Biotech and Blockchain - OneSafe
Leap Therapeutics (LPTX) Stock: Soars 58% After $58.9M PIPE Deal with Winklevoss Capital to Launch Crypto Treasury - CoinCentral
Winklevoss-Backed Leap Therapeutics to Start Crypto Treasury - The Crypto Times
Leap Therapeutics (LPTX) Stock Jumps on $58M Winklevoss-Led Crypto Deal - parameter.io
Leap Therapeutics Announces $58.88M Private Placement Led by Winklevoss Capital - citybiz
Leap Therapeutics stock soars after securing $58.9M investment By Investing.com - Investing.com
Biotech Goes Bitcoin: Leap Therapeutics Surges 29% on Groundbreaking Crypto Treasury Deal with Winklevoss Capital - FinancialContent
Leap Therapeutics Gains 25% on Crypto Deal - CoinDesk
Leap Therapeutics (LPTX) Secures $58.9M Financing for Growth Ini - GuruFocus
Leap Therapeutics (LPTX) Announces Strategic Investment and Boar - GuruFocus
Leap therapeutics secures $58.9 million for digital asset strategy By Investing.com - Investing.com Canada
Leap Therapeutics raises $58.9M in private placement for digital assets - Investing.com Canada
Leap therapeutics secures $58.9 million for digital asset strategy - Investing.com India
Leap Therapeutics Surges on Winklevoss-Led Cash Boost for Crypto Treasury Gamble - RagingBull
$58.9M Raise: Leap Therapeutics Starts Digital Asset Treasury; Winklevoss to Nominate Two Board Members - Stock Titan
Can volume confirm reversal in Leap Therapeutics Inc.2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Reversal indicators forming on Leap Therapeutics Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Based Signals - newser.com
Published on: 2025-10-06 03:41:46 - newser.com
Will Leap Therapeutics Inc. (5MC) stock remain on Wall Street radarWall Street Watch & Reliable Intraday Trade Alerts - newser.com
Heatmap analysis for Leap Therapeutics Inc. and competitorsTake Profit & Verified Momentum Stock Ideas - newser.com
Is Leap Therapeutics Inc. (5MC) stock cheap vs fundamentalsPortfolio Profit Report & Free Community Consensus Stock Picks - newser.com
Published on: 2025-10-05 02:35:13 - newser.com
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data - FinancialContent
What consensus target says about Leap Therapeutics Inc. (5MC) stockWeekly Trade Analysis & Consistent Profit Trade Alerts - newser.com
Is now a turning point for Leap Therapeutics Inc.Weekly Volume Report & Growth Focused Investment Plans - newser.com
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):